Financial Performance - The company's revenue for Q3 2022 reached ¥1,658,020,093.78, representing a 28.45% increase year-over-year[3] - Net profit attributable to shareholders was ¥542,739,578.90, an increase of 11.73% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥542,048,671.13, up by 9.92% year-over-year[3] - The company's operating income for the year-to-date reached ¥4,951,543,979.15, a significant increase of 62.53% year-over-year, driven by growth in imported albumin sales[6] - Total revenue for the current period reached ¥4,951,543,979.15, a significant increase from ¥3,046,522,817.78 in the previous period, representing a growth of approximately 62.5%[15] - Operating profit for the current period was ¥1,900,857,794.52, compared to ¥1,588,850,419.93 in the previous period, indicating an increase of about 19.6%[16] - Net profit attributable to shareholders of the parent company was ¥1,603,811,643.64, up from ¥1,396,174,488.18, reflecting a growth of approximately 14.9%[16] - The comprehensive income attributable to the parent company for the current period was ¥3,072,458,542.24, compared to ¥1,305,441,786.15 in the same period last year[17] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥30,228,237,255.47, reflecting a 10.98% increase from the end of the previous year[3] - Total assets increased to ¥30,228,237,255.47 from ¥27,236,582,048.82, marking a rise of about 11.6%[15] - Non-current assets totaled ¥22,287,466,066.89, up from ¥20,364,331,133.06, which is an increase of approximately 9.4%[15] - Current liabilities rose to ¥1,422,394,257.08 from ¥1,306,625,745.51, representing an increase of about 8.9%[15] - Total liabilities increased to ¥1,422,394,257.08 from ¥1,306,625,745.51, indicating a rise of about 8.9%[34] - The total equity attributable to shareholders of the parent company rose to ¥28,786,765,664.31 from ¥25,902,445,517.58, indicating an increase of approximately 11.1%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,203,356,366.64, showing a slight increase of 1.96% compared to the previous year[3] - The company's cash and cash equivalents as of September 30, 2022, amounted to approximately ¥3.17 billion, an increase from ¥2.75 billion at the beginning of the year[13] - The company reported a net cash increase of ¥-68,862,752.42 in cash and cash equivalents for the current period[19] - The net increase in cash and cash equivalents was CNY -68,862,752.42, compared to a positive increase of CNY 159,074,397.72 in the prior year, indicating liquidity challenges[39] Shareholder Information - The total number of common shareholders at the end of the reporting period was 121,818[7] - GRIFOLS, S.A. is the largest shareholder, holding 26.20% of shares, equivalent to 1,766,165,808 shares[7] - The second largest shareholder, RAAS CHINA LIMITED, holds 5.83% of shares, totaling 392,878,676 shares[7] Research and Development - Research and development expenses increased by 31.32% to ¥102,089,434.95, indicating a focus on enhancing project development[6] - Research and development expenses for the current period were ¥102,089,434.95, compared to ¥77,743,274.40 in the previous period, showing an increase of approximately 31.3%[16] Operating Costs - The company experienced a 93.00% increase in operating costs, amounting to ¥2,716,933,294.97, largely due to the higher proportion of imported albumin sales[6] - The total operating costs for the current period were ¥3,352,262,703.29, up from ¥1,899,585,559.02, indicating an increase of about 76.7%[36] Other Financial Metrics - The company's basic earnings per share for the period was ¥0.081, a 12.50% increase compared to the same period last year[3] - The company's weighted average return on net assets was 5.86%, an increase of 0.43 percentage points year-on-year[23] - Other comprehensive income after tax for the current period was ¥1,468,646,898.60, a significant improvement from -¥90,732,702.03 in the previous period[16]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,293,523,885.37, representing an increase of 87.59% compared to CNY 1,755,724,588.09 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was CNY 1,061,072,064.74, up 16.55% from CNY 910,429,461.76 year-on-year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,058,972,524.69, reflecting a 14.60% increase from CNY 924,079,257.01 in the previous year[13]. - The net cash flow from operating activities was CNY 764,952,685.41, which is a 33.88% increase compared to CNY 571,392,608.76 in the same period last year[13]. - Basic earnings per share were CNY 0.157, an increase of 16.30% from CNY 0.135 in the previous year[13]. - The total assets at the end of the reporting period were CNY 28,998,624,640.89, a 6.47% increase from CNY 27,236,582,048.82 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company were CNY 27,460,676,505.19, up 6.02% from CNY 25,902,445,517.58 at the end of the previous year[13]. - The weighted average return on net assets was 3.96%, an increase of 0.39 percentage points from 3.57% in the previous year[13]. - The company reported a comprehensive income of CNY -555,535,423.29 for the first half of 2022, an improvement from CNY -1,240,845,030.34 in the same period of 2021[131]. - The total profit for the first half of 2022 was CNY 1,263,803,505.79, up 23.4% from CNY 1,024,465,706.37 in the same period of 2021[134]. Revenue Sources - Revenue from blood products production and sales was ¥3,292,768,512.38, accounting for 99.97% of total revenue, with a year-on-year increase of 87.60%[31]. - Albumin sales surged to ¥2,144,745,502.59, representing a 207.26% increase year-on-year[31]. - Import of albumin saw a dramatic rise to ¥1,409,961,396.69, marking an increase of 1,748.42% compared to the previous year[32]. - The East China region generated ¥1,172,307,264.26 in revenue, reflecting an 87.90% increase year-on-year[32]. Investment and Acquisitions - The company has successfully integrated acquisitions, enhancing its core competitiveness and significantly increasing raw plasma collection volume[27]. - The company has completed the acquisition of Zhejiang Haikang's equity using RMB 24,522.05 million from the remaining fundraising[46]. - The acquisition of Zhejiang Haikang equity was completed on December 26, 2016, with a total transaction price of CNY 369 million for 90% of the equity[56]. - The company has a 45% stake in GDS, with an asset scale of 13.905 billion RMB, located in Europe and the United States, focusing on procurement, manufacturing, and sales of medical and blood testing products[36]. Research and Development - Research and development investment increased by 46.03% to CNY 64.23 million, reflecting the company's commitment to project development[30]. - Research and development expenses increased to CNY 64,231,731.95, up 46.0% from CNY 43,985,695.12 in the prior period[134]. Risk Management - The management has highlighted potential risks and corresponding measures in the report, which investors are advised to review[2]. - The company faces risks related to the supply of raw materials, with a focus on enhancing management of plasma collection stations to increase supply capacity[61]. - The company has a risk of goodwill impairment due to the consolidation of subsidiaries, which requires annual impairment testing[63]. Environmental Compliance - The company’s wastewater treatment process includes regulation, acid hydrolysis, aerobic treatment, contact oxidation, and disinfection[70]. - The company has implemented noise reduction measures in its facilities to ensure compliance with noise standards[74]. - All companies reported no administrative penalties due to environmental issues during the reporting period, reflecting strong compliance[87]. - Shanghai Laishi obtained the "2019 Annual Environmental Protection Advanced Collective" award in April 2020[91]. Shareholder Information - Grifols, S.A. holds 1,766,165,808 shares, representing 26.20% of the total shares, and is the largest shareholder[115]. - The second-largest shareholder, RAAS China Limited, holds 495,769,852 shares, accounting for 7.35% of the total[115]. - The company has a total of 126,480 common shareholders at the end of the reporting period[115]. - The report indicates that 484,528,274 shares held by Grifols, S.A. are pledged[115]. Financial Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and storage of funds[47]. - The total amount of raised funds is 638.7271 million RMB, with 170.10 thousand RMB used in the current period and a cumulative usage of 578.7344 million RMB[43]. - The company has not changed the purpose of the raised funds during the reporting period, with 7.71387 million RMB remaining unused[43]. Operational Efficiency - The company aims to enhance its quality assurance system to address potential safety risks associated with blood products[60]. - The company plans to continue expanding its market presence and invest in new product development[149]. - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive growth[149]. Accounting Policies - The financial statements comply with the accounting standards set by the Ministry of Finance, accurately reflecting the company's consolidated financial position as of June 30, 2022[163]. - The company has implemented new financial instrument standards and revenue recognition standards since 2019, ensuring compliance with the Ministry of Finance's regulations[161]. - The company categorizes receivables into groups based on historical experience and aging to estimate expected credit losses[185].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,685,498,423.72, representing a 97.32% increase compared to RMB 854,205,643.53 in the same period last year[4]. - Net profit attributable to shareholders was RMB 548,033,363.89, up 28.63% from RMB 426,048,265.01 year-on-year[4]. - The net cash flow from operating activities increased by 44.25% to RMB 415,302,906.87, compared to RMB 287,898,726.08 in the previous year[4]. - The basic and diluted earnings per share were both RMB 0.081, reflecting a 28.57% increase from RMB 0.063 in the same period last year[4]. - The net profit margin improved to approximately 32.4% in Q1 2022, compared to 49.7% in the same period last year, indicating a shift in profitability dynamics[17]. - The total profit for Q1 2022 was CNY 645,212,896.49, an increase of 35.6% from CNY 475,740,853.68 in Q1 2021[39]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 27,698,268,156.38, a 1.70% increase from RMB 27,236,582,048.82 at the end of the previous year[4]. - The total assets of Shanghai RAAS Blood Products Co., Ltd. reached approximately CNY 27.70 billion as of March 31, 2022, an increase from CNY 27.24 billion at the beginning of the year, reflecting a growth of about 1.68%[12][13]. - The company's total liabilities decreased slightly to ¥1,314,844,595.07 from ¥1,332,415,396.48, showing a reduction of approximately 1.3%[15]. - The company's accounts payable decreased to CNY 933.69 million from CNY 966.05 million, a reduction of approximately 3.35%[13]. Cash Flow - The company's cash and cash equivalents amounted to CNY 3.02 billion, up from CNY 2.75 billion at the beginning of the year, representing an increase of approximately 10.05%[12]. - The cash flow from operating activities netted CNY 415,302,906.87, compared to CNY 287,898,726.08 in the previous year, indicating a rise of 44.3%[42]. - The company reported a net cash outflow from investing activities of ¥66,788,256.17, an improvement from a net outflow of ¥85,298,102.62 in the same period last year[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 132,064, with the largest shareholder, GRIFOLS, S.A., holding 26.20% of the shares[10]. - The total equity attributable to shareholders increased to ¥26,383,748,240.39 from ¥25,902,445,517.58, reflecting a growth of about 1.8%[36]. Research and Development - Research and development expenses rose by 62.59% to RMB 34,400,140.41, driven by increased R&D activities[9]. - The company is actively engaged in research and development of new products and technologies to enhance its market position[11]. - The company reported R&D expenses of ¥34,400,140.41 for Q1 2022, an increase from ¥21,157,204.66 in the same period last year, representing a growth of approximately 62.3%[38]. Investment Income - The company reported a decrease in investment income by 30.15% to RMB 110,489,501.71, attributed to reduced investment income from associated companies[9]. - The company's investment income decreased by 30.15% to CNY 110,489,501.71, primarily due to reduced investment returns from associated companies[31]. Future Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[11].